India Pharma Outlook Team | Thursday, 17 February 2022
Despite concerns over the safety of anti-Covid drug molnupiravir, Indians have purchased around 1.2 crore pills worth Rs 50 crore within the first month of its launch, data shows. According to the latest information from health research firm IQVIA, molnupiravir has registered a turnover of Rs 46.5 crore with Hetero’s Movfor registering the highest
sales in terms of revenue and JB Chemicals’ Molnumax in terms of maximum units sold. The first oral anti-Covid drug, molnupiravir, was approved in the last week of December by the country’s apex health regulator Drugs Controller General of India (DCGI).
Thirteen Indian pharmaceutical companies, including Torrent, Cipla, Sun Pharma, Dr Reddy’s, Natco, Mylan, Hetero, and Optimus were given the clearances to manufacture molnupiravir, which is being developed by US-based biotechnology company Ridgeback Biotherapeutics in collaboration with American pharma giant Merck.
The drug was touted as the magic bullet and a game changer because the studies showed that it could cut the risk of hospitalisation and death by a third among those infected by the coronavirus.
, CDSCO.jpg)
